Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Thermo Fisher, NAMSA, DNA Script, and More

NEW YORK (GenomeWeb) – Thermo Fisher Scientific's board this week declared a quarterly cash dividend of $.17 per share, payable on Oct. 15 to shareholders of record on Sept. 17.

Medical Research Organization NAMSA said this week it has launched its in vitro diagnostic development business to aid manufacturers expedite commercialization of its products. Based in Ohio, NAMSA offers its Uniquely IVD regulatory, quality, and clinical research services. Among the services the company provides are guidance on 510(k) submissions and CE marking, as well as clinical research, biostatistics, and data management, according to its website.


DNA Script announced this week it has been awarded $2.7 million in non-dilutive financing from the Bpifrance Concours d'Innovation program. The financing, which the company will receive as subsidies and refundable advances, was awarded for the company’s enzymatic DNA synthesis technology and based on the company’s potential in biomanufacturing for cell and gene therapy, DNA Script said. The firm is one of eight companies to receive an award in the Concours d'Innovation 2018  competition, in the Healthcare division. This competitive grant is dedicated to innovative projects aimed at accelerating the emergence of companies with the potential to become world leaders in their respective markets. Other firms that also won awards in this division in 2018 include a company called MilliDrop Instrument, which is developing a diagnostic to rapidly isolate infectious bacteria and potential antibiotic resistance in patients in less than 24 hours, which the company said is one to two days faster than existing methods; and a firm called Myriade, which is developing a system for the identification and characterization of organic and inorganic nanoparticles, which the company said could be used for the analysis of the gut microbiome.

Flagship Biosciences this week announced the closing of its Series A funding round to advance the growth of its computational tissue image analysis technology platform and biomarker-based diagnostics and drug development services. The firm did not disclose the amount of the financing. In addition to advancing the development of its tissue image analysis software and operational workflow, Flagship said that the funds will go toward increasing its commercial footprint to drive drug development partnerships and precision medicine.

Biotech company Orig3n this week announced the initial close of Series B financing round, with Haitong International serving as the lead investor. The company did not disclose the amount raised in the funding round but noted it has raised more than $50 million in capital to date since it was founded in 2014. The Series B financing will support Orig3n's international and domestic expansion, as well as R&D for new products, and continued development of Orig3n's regenerative medicine treatments using its allogenic bank of cells that is HLA-matched to 90 percent of the US population.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.